Study drug combo for advanced solid tumors
Treatments studied
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cancer (solid tumor) that is advanced or has spread and cannot be removed with surgery.
- Your cancer has grown or you couldn't tolerate treatment with at least one prior standard therapy.
- You have not been treated with certain types of immunotherapy (specifically drugs targeting CTLA-4).
- You do not have active cancer that has spread to the brain.
- You are healthy enough to be up and about, even if you need to rest sometimes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
This trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and whether it can shrink tumors or slow their growth.
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.